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Purpose: Osteoarthritis (OA) is characterized by excess degrada-
tion of articular cartilage. Although pro-inﬂammatory cytokines
such as interleukin-1 (IL-1) are recognized to be destructive
mediators in OA, increasing evidence also suggests that other
mechanisms exist to drive the pathological destruction of carti-
lage in OA. There are considerable data to implicate the matrix
metalloproteinases (MMPs) in this degradation, but emerging evi-
dence now also implicates serine proteinases with roles in tissue
turnover.
This study aimed to assess the role of the transmembrane serine
proteinase matriptase in cartilage destruction.
Methods: Matripase gene expression was analysed in OA and
normal (neck of femur (NOF)) cartilage and synovium by TaqMan
low density array. Immunolocalisation was performed on OA car-
tilage. Ex vivo models of cartilage degradation were used with
the most potent cytokine stimulus reported to promote cartilage
catabolism, namely IL-1 in combination with oncostatin M (OSM).
The effect of exogenous matriptase was also assessed, including
the assessment of collagenase production (immunoassay) and
activity (bioassay), whilst MMP gene expression was assessed
by real-time PCR. The ability of matriptase to process proMMPs
was assessed using SDS-PAGE whilst the ability of matriptase to
activate protease-activated receptor-2 (PAR-2) was performed in
a blood perfusion assay in wild-type and PAR-2 knockout mouse
joints.
Results: Matripase gene expression was signiﬁcantly elevated in
cartilage and synovium in OA patients compared to normal (NOF),
and matriptase was localized to OA chondrocytes by histology.
Addition of matriptase to IL-1+OSM-stimulated bovine and hu-
man cartilage caused a signiﬁcant increase in collagen release
compared to IL-1+OSM alone at day 7. Moreover, matriptase
alone caused signiﬁcant collagenolysis from OA cartilage which
was abolished by the inclusion of a metalloproteinase inhibitor
(GM6001), and also caused signiﬁcant increases in MMP-1 and
MMP-13 gene expression. We also demonstrated that matripase
activates proMMP-1 (but not proMMP-13), conﬁrmed it to be a
proMMP-3 activator and demonstrated that matriptase enhances
synovial perfusion in wild-type mice but not in PAR-2 knockout
littermates.
Conclusions: Our data conﬁrm that matriptase is expressed by
OA chondrocytes and that this expression is elevated compared to
normal cartilage. Matriptase is an activator of both proMMP-1 and
proMMP-3 which may account for the early and enhanced collagen
release seen. We also demonstrated that matriptase alone led to
increased expression of MMP-1 and MMP-13 in OA cartilage, im-
plying that this serine proteinase has both direct (MMP activation)
and indirect (MMP expression) mechanisms of action that drive
cartilage destruction in OA. The indirect mechanism is likely to be
via PAR-2-mediated effects, and a more detailed understanding of
these mechanisms may well highlight new therapeutic targets for
OA treatment.
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Purpose: The relative role of ADAMTS4 and 5 in aggrecan degra-
dation in response to cytokines, and the importance of their
C-terminal ancillary domains on their ability to cleave the CS-2
region, were investigated.
Methods: Bovine articular cartilage explants were cultured in the
presence of IL-1β, TNFα and OSM, alone or in combinations
for up to 8 days. Release of GAG-bearing fragments from the
tissue was determined by the DMMB assay. Aggrecan degradation
was monitored by immunoblot analysis of tissue extracts and
media samples for aggrecan G1 and G3-containing catabolites.
ADAMTS4 and ADAMTS5 mRNA expression in the tissue was
determined at day 2 of cytokine treatment by real-time PCR.
Recombinant human full-length aggrecanases, (ADAMTS4-1 and
ADAMTS5-1), and two domain deletion variants (ADAMTS5-2,
lacking the C-terminal thrombospondin domain; and ADAMTS5-4,
also lacking the spacer and cysteine-rich domains) were used
to study aggrecanase-mediated aggrecan degradation in vitro.
Fetal bovine aggrecan was incubated with the various isoforms
and the digestion products were analyzed by SDS/PAGE and
immunoblotting.
Results: While there was an increase in GAG release from IL-1β,
TNFα or OSM-treated cartilage, this occurred most rapidly with
combinations of IL-1β/OSM and TNFα/OSM. Immunoblot analy-
sis of aggrecan catabolites revealed that the molecular sizes of
the aggrecan fragments generated upon cytokine treatment were
consistent with aggrecanase-mediated cleavage in the IGD and
CS-2 region of aggrecan. However, in the presence of OSM, a
unique 50 kDa 2048Ala-G3 degradation product was observed.
No sign of aggrecan-degrading proteolytic activity other than that
due to aggrecanases was observed under any cytokine treatment.
Real-time PCR analysis demonstrated that under all cytokine treat-
ments, the expression of ADAMTS4 was more highly stimulated
than ADAMTS5, and the level of stimulation was maximal with of
IL-1β/OSM and TNFα/OSM mixtures. However, irrespective of the
cytokine treatment, ADAMTS5 mRNA levels were always more
abundant than those of ADAMTS4. Aggrecan digestion studies
using the full-length ADAMTS5-1 isoform revealed that the 50 kDa
product is generated and accumulates as the major aggrecan
catabolite by conversion of a previously generated 1872Leu-G3
fragment. In contrast, ADAMTS4-1 was far less potent at gener-
ating this product. Aggrecan digestions with the domain deletion
forms demonstrated that cleavage at the Glu2047-Ala2048 bond
is dependent on the presence of the C-terminal spacer and/or
cysteine-rich domains of ADAMTS5.
Conclusions: This study demonstrates that, in short term cul-
tures, aggrecanases are the only proteinases involved in aggrecan
degradation in cartilage stimulated with IL-1β, TNFα or OSM, and
that, in the presence of OSM, aggrecan cleavage within the CS-2
region is more extensive. While it is likely that both aggrecanases
always participate in cytokine-mediated aggrecan degradation, this
study shows that the unique degradation pattern of the CS-2 re-
gion observed in the presence of OSM can be ascribed to the
action of ADAMTS5 and is dependent on the enzyme isoform
present in the tissue.
